Abstract Background A previous European Headache Federation (EHF) guideline
addressed the use of monoclonal antibodies targeting the calcitonin gene-related peptide …

Abstract Treatment of migraine is on the cusp of a new era with the development of drugs
that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its …

Background Atogepant is an oral, small-molecule, calcitonin gene–related peptide receptor
antagonist that is being investigated for the preventive treatment of migraine. Methods In a …

Objective To incorporate recent research findings, expert consensus, and patient
perspectives into updated guidance on the use of new acute and preventive treatments for …

Background Rimegepant is a calcitonin gene-related peptide receptor antagonist that has
shown efficacy and safety in the acute treatment of migraine. We aimed to compare the …

Background Antibodies targeting calcitonin gene-related peptide (CGRP) or its receptor
have shown efficacy in the prevention of migraine attacks. We investigated the efficacy and …

Objective To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin
gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine …

Background A substantial proportion of patients with migraine does not respond to, or
cannot tolerate, oral preventive treatments. Erenumab is a novel CGRP-receptor antibody …

Sensitization of trigeminal ganglion neurons contributes to primary headache disorders such
as migraine, but the specific neuronal and non-neuronal trigeminal subtypes that are …

Migraine is one of the most prevalent and disabling diseases worldwide, but until recently,
few migraine-specific therapies had been developed. Extensive basic and clinical scientific …